Aarti Drugs Limited reported its financial results for the fourth quarter ended March 31, 2025, showcasing a significant improvement in profitability. The company posted a consolidated net profit of ₹62.8 crore in Q4FY25, up 32.7% from ₹47.4 crore in the same quarter last year. This improvement comes despite a marginal dip in operating revenue.
The company’s revenue from operations for the quarter stood at ₹676.8 crore, down 9.1% year-on-year from ₹619.9 crore reported in Q4FY24. However, strong cost management and a fall in certain operating expenses contributed to improved bottom-line performance.
The total income for Q4FY25 was ₹678.6 crore. Operating expenses came in at ₹607.5 crore, and the company’s profit before tax stood at ₹71.1 crore, rising from ₹64.2 crore YoY. Tax expenses were significantly lower at ₹8.38 crore versus ₹18.7 crore in the previous year.
On a full-year basis, Aarti Drugs reported a net profit of ₹168.1 crore in FY25, marginally lower than ₹171.4 crore reported in FY24. Revenue for the year stood at ₹2,387 crore, also lower than ₹2,585 crore recorded last year.
Key Q4FY25 Highlights (YoY):
-
Revenue: ₹676.8 crore vs ₹619.9 crore (↑9.1%)
-
Net Profit: ₹62.8 crore vs ₹47.4 crore (↑32.7%)
-
Profit Before Tax: ₹71.1 crore vs ₹64.2 crore
-
Total Income: ₹678.6 crore vs ₹621 crore
-
Total Expenses: ₹607.5 crore vs ₹556.9 crore
Disclaimer: The information provided is for informational purposes only and should not be considered financial or investment advice. Stock market investments are subject to market risks. Always conduct your own research or consult a financial advisor before making investment decisions. Author or Business Upturn is not liable for any losses arising from the use of this information.
